ANNALS OF HEMATOLOGY-期刊论坛，投稿经验-MedSci.cn

[GetPortalCommentsPageByObjectIdResponse(id=2237488, encodeId=1155223e488ce, content=审稿速度:6.0 | 投稿命中率:50.0 偏重的研究方向：临床研究;移植预处理方案;前瞻，2期，单臂研究 经验分享：前期经过5次拒稿，我2024年1月14投稿Annals of hematology，2024年1月31编辑审核后送外审，2024年7月10日收到修改意见，2024年8月23收到文章被接受的消息，9月份线上发表，11月正式见刊，真的很开心，文章的顺利接受也带给我了信心，让我继续完成第二篇文章的创作，期待好的结果，也希望把这份好运气带给每一位投稿人，不管什么时候都不要放弃，你的文章一定会有属于它的一个家会接收它！加油，我们都很棒！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=42, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/202411/53b4a1217f3a4e079e3eaf104e804c09-leSA8mUKFk8P.jpg, createdBy=d5908847710, createdName=ms4000000203499871, createdTime=Sun Nov 17 22:09:53 CST 2024, time=2024-11-17, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=577471, encodeId=68545e74718d, content=我也130****6528 2019-10-03 00:00:00 发表: With editor已经三个月了，想撤稿, beContent=130****6528 2019-10-03 00:00:00 发表: With editor已经三个月了，想撤稿, objectType=tool_impact_factor, channel=null, level=null, likeNumber=147, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=17c95089935, createdName=145cf120m10(暂无昵称), createdTime=Tue Oct 08 00:00:00 CST 2019, time=2019-10-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2197970, encodeId=2f3a219e970d7, content=质量检查就10天了，崩溃, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=130, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6bbb4799156, createdName=2606467171, createdTime=Thu Apr 11 13:43:26 CST 2024, time=2024-04-11, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2243217, encodeId=14cd224321ecb, content=偏重的研究方向：白血病 经验分享：投了两篇letter，2个月了还是显示with editor ，求教各位大神正常吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTL8GV06roPeF96gmNNe5qicpI81qEbXLy1oKu8HDafssvuSfccR9UQIFkFFESxJ0ECOjgVoAt6QlaQ/132, createdBy=50201623070, createdName=wylj, createdTime=Wed Dec 18 06:28:28 CST 2024, time=2024-12-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2241787, encodeId=43762241e8705, content=我的投稿从系统里消失了，前几天还好好的，已经送外审了，从昨天点进去一看根本找不到我的文章了，也没有任何被拒的痕迹或者邮件，而且好像springer nature下的各期刊都没有自己的主页，所以我找不到annals of hematology可以联系的邮箱，大家有遇到过这种情况吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1f218759120, createdName=ms3000001014938846, createdTime=Wed Dec 11 09:58:30 CST 2024, time=2024-12-11, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2183703, encodeId=792f2183e038c, content=审稿速度:2.0 | 投稿命中率:75.0 经验分享：投白血病相关的综述，2个审稿人，提的意见比较中肯，审稿速度很快 2023-11-23 投稿 2023-11-28 editor assigned 2023-11-29 Under Review 2023-12-12 Major revision 2023-12-26 Submitted to journal 2023-12-27 Under Review 2024-01-15 minor revision 2024-01-16 Submitted to journal 2024-01-19 Submission accepted , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=147, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=775c5640894, createdName=ms8000000428100640, createdTime=Wed Jan 24 16:20:42 CST 2024, time=2024-01-24, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2164043, encodeId=1dea21640439d, content=审稿速度:1.0 | 投稿命中率:75.0 偏重的研究方向：肿瘤;血液病 经验分享：根据投稿指南要求修改排版，表达准确，图表清晰度够，审稿快，通过率高 2023-08-31投稿 2023-09-05 with editor 2023-09-01 Under Review 2023-09-19 Major revise 2023-10-13 Submitted to journal 203-10-16 Under Review 2023-10-20 accepted, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=267, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6a638109651, createdName=清清欢, createdTime=Sat Oct 21 07:35:27 CST 2023, time=2023-10-21, status=1, ipAttribution=江西省), GetPortalCommentsPageByObjectIdResponse(id=2125680, encodeId=4cce21256806c, content=2022.12.15投稿 2023.04.08 两个审稿人给了意见 2023.04.11修回 4.13接受编辑很客气, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=191, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210911/5888f6640265430b902b3fded856f491/788d7d25b2f7419ab0fab8df4239cea1.jpg, createdBy=c0775397989, createdName=凶巴巴恰北北怪兽, createdTime=Thu Apr 13 13:55:16 CST 2023, time=2023-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=926986, encodeId=b5b192698693, content=审稿速度:2.0 | 投稿命中率:50.0 经验分享：2020-09-04 投稿 2020-09-10 with editor 2020-10-02 Under Review 2020-11-11 Major Revision 2021-02-01 大修返回去 2021-02-02 with editor 2021-02-24 Accept 两个审稿人，大约提了20个问题，许多都是我们当时刻意回避的，审稿人都提出来了，在大修中认真回答审稿人的问题，让做亚组分析就做亚组分析，不能补充的内容就实话实说，告知审稿人我们的困难。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=337, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLfmR4mafTv9yhHTykjCcGOQP5acHwbYj07fiaDoT6p8jxes2icO8n9R8BD8t0LJmg1SjlPiaqWZn33g/132, createdBy=5c971339316, createdName=bright120, createdTime=Wed Feb 24 23:39:35 CST 2021, time=2021-02-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=574755, encodeId=e42c5e47558e, content=三个月了，一审还在under review。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=237, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/eunqL11r55A8WAWlyWs0EnafPqUs8awD2Jsk71ggkmlWicOGpfTScjbNxecDibU9J2TQjcVafFgY0hju6sfJS9rQ/132, createdBy=c6852367423, createdName=122e6881m72暂无昵称, createdTime=Tue Aug 13 21:09:00 CST 2019, time=2019-08-13, status=1, ipAttribution=)]

2024-11-17 ms4000000203499871 来自北京

审稿速度:6.0 | 投稿命中率:50.0
偏重的研究方向：临床研究;移植预处理方案;前瞻，2期，单臂研究
经验分享：前期经过5次拒稿，我2024年1月14投稿Annals of hematology，2024年1月31编辑审核后送外审，2024年7月10日收到修改意见，2024年8月23收到文章被接受的消息，9月份线上发表，11月正式见刊，真的很开心，文章的顺利接受也带给我了信心，让我继续完成第二篇文章的创作，期待好的结果，也希望把这份好运气带给每一位投稿人，不管什么时候都不要放弃，你的文章一定会有属于它的一个家会接收它！加油，我们都很棒！

42 2

展开2条回复

[GetPortalCommentsPageByObjectIdResponse(id=2237488, encodeId=1155223e488ce, content=审稿速度:6.0 | 投稿命中率:50.0 偏重的研究方向：临床研究;移植预处理方案;前瞻，2期，单臂研究 经验分享：前期经过5次拒稿，我2024年1月14投稿Annals of hematology，2024年1月31编辑审核后送外审，2024年7月10日收到修改意见，2024年8月23收到文章被接受的消息，9月份线上发表，11月正式见刊，真的很开心，文章的顺利接受也带给我了信心，让我继续完成第二篇文章的创作，期待好的结果，也希望把这份好运气带给每一位投稿人，不管什么时候都不要放弃，你的文章一定会有属于它的一个家会接收它！加油，我们都很棒！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=42, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/202411/53b4a1217f3a4e079e3eaf104e804c09-leSA8mUKFk8P.jpg, createdBy=d5908847710, createdName=ms4000000203499871, createdTime=Sun Nov 17 22:09:53 CST 2024, time=2024-11-17, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=577471, encodeId=68545e74718d, content=我也130****6528 2019-10-03 00:00:00 发表: With editor已经三个月了，想撤稿, beContent=130****6528 2019-10-03 00:00:00 发表: With editor已经三个月了，想撤稿, objectType=tool_impact_factor, channel=null, level=null, likeNumber=147, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=17c95089935, createdName=145cf120m10(暂无昵称), createdTime=Tue Oct 08 00:00:00 CST 2019, time=2019-10-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2197970, encodeId=2f3a219e970d7, content=质量检查就10天了，崩溃, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=130, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6bbb4799156, createdName=2606467171, createdTime=Thu Apr 11 13:43:26 CST 2024, time=2024-04-11, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2243217, encodeId=14cd224321ecb, content=偏重的研究方向：白血病 经验分享：投了两篇letter，2个月了还是显示with editor ，求教各位大神正常吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTL8GV06roPeF96gmNNe5qicpI81qEbXLy1oKu8HDafssvuSfccR9UQIFkFFESxJ0ECOjgVoAt6QlaQ/132, createdBy=50201623070, createdName=wylj, createdTime=Wed Dec 18 06:28:28 CST 2024, time=2024-12-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2241787, encodeId=43762241e8705, content=我的投稿从系统里消失了，前几天还好好的，已经送外审了，从昨天点进去一看根本找不到我的文章了，也没有任何被拒的痕迹或者邮件，而且好像springer nature下的各期刊都没有自己的主页，所以我找不到annals of hematology可以联系的邮箱，大家有遇到过这种情况吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1f218759120, createdName=ms3000001014938846, createdTime=Wed Dec 11 09:58:30 CST 2024, time=2024-12-11, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2183703, encodeId=792f2183e038c, content=审稿速度:2.0 | 投稿命中率:75.0 经验分享：投白血病相关的综述，2个审稿人，提的意见比较中肯，审稿速度很快 2023-11-23 投稿 2023-11-28 editor assigned 2023-11-29 Under Review 2023-12-12 Major revision 2023-12-26 Submitted to journal 2023-12-27 Under Review 2024-01-15 minor revision 2024-01-16 Submitted to journal 2024-01-19 Submission accepted , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=147, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=775c5640894, createdName=ms8000000428100640, createdTime=Wed Jan 24 16:20:42 CST 2024, time=2024-01-24, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2164043, encodeId=1dea21640439d, content=审稿速度:1.0 | 投稿命中率:75.0 偏重的研究方向：肿瘤;血液病 经验分享：根据投稿指南要求修改排版，表达准确，图表清晰度够，审稿快，通过率高 2023-08-31投稿 2023-09-05 with editor 2023-09-01 Under Review 2023-09-19 Major revise 2023-10-13 Submitted to journal 203-10-16 Under Review 2023-10-20 accepted, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=267, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6a638109651, createdName=清清欢, createdTime=Sat Oct 21 07:35:27 CST 2023, time=2023-10-21, status=1, ipAttribution=江西省), GetPortalCommentsPageByObjectIdResponse(id=2125680, encodeId=4cce21256806c, content=2022.12.15投稿 2023.04.08 两个审稿人给了意见 2023.04.11修回 4.13接受编辑很客气, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=191, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210911/5888f6640265430b902b3fded856f491/788d7d25b2f7419ab0fab8df4239cea1.jpg, createdBy=c0775397989, createdName=凶巴巴恰北北怪兽, createdTime=Thu Apr 13 13:55:16 CST 2023, time=2023-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=926986, encodeId=b5b192698693, content=审稿速度:2.0 | 投稿命中率:50.0 经验分享：2020-09-04 投稿 2020-09-10 with editor 2020-10-02 Under Review 2020-11-11 Major Revision 2021-02-01 大修返回去 2021-02-02 with editor 2021-02-24 Accept 两个审稿人，大约提了20个问题，许多都是我们当时刻意回避的，审稿人都提出来了，在大修中认真回答审稿人的问题，让做亚组分析就做亚组分析，不能补充的内容就实话实说，告知审稿人我们的困难。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=337, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLfmR4mafTv9yhHTykjCcGOQP5acHwbYj07fiaDoT6p8jxes2icO8n9R8BD8t0LJmg1SjlPiaqWZn33g/132, createdBy=5c971339316, createdName=bright120, createdTime=Wed Feb 24 23:39:35 CST 2021, time=2021-02-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=574755, encodeId=e42c5e47558e, content=三个月了，一审还在under review。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=237, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/eunqL11r55A8WAWlyWs0EnafPqUs8awD2Jsk71ggkmlWicOGpfTScjbNxecDibU9J2TQjcVafFgY0hju6sfJS9rQ/132, createdBy=c6852367423, createdName=122e6881m72暂无昵称, createdTime=Tue Aug 13 21:09:00 CST 2019, time=2019-08-13, status=1, ipAttribution=)]

2019-10-08 145cf120m10(暂无昵称)

我也130****6528 2019-10-03 00:00:00 发表:
With editor已经三个月了，想撤稿

130****6528 2019-10-03 00:00:00 发表: With editor已经三个月了，想撤稿

147 7

展开7条回复

[GetPortalCommentsPageByObjectIdResponse(id=2237488, encodeId=1155223e488ce, content=审稿速度:6.0 | 投稿命中率:50.0 偏重的研究方向：临床研究;移植预处理方案;前瞻，2期，单臂研究 经验分享：前期经过5次拒稿，我2024年1月14投稿Annals of hematology，2024年1月31编辑审核后送外审，2024年7月10日收到修改意见，2024年8月23收到文章被接受的消息，9月份线上发表，11月正式见刊，真的很开心，文章的顺利接受也带给我了信心，让我继续完成第二篇文章的创作，期待好的结果，也希望把这份好运气带给每一位投稿人，不管什么时候都不要放弃，你的文章一定会有属于它的一个家会接收它！加油，我们都很棒！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=42, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/202411/53b4a1217f3a4e079e3eaf104e804c09-leSA8mUKFk8P.jpg, createdBy=d5908847710, createdName=ms4000000203499871, createdTime=Sun Nov 17 22:09:53 CST 2024, time=2024-11-17, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=577471, encodeId=68545e74718d, content=我也130****6528 2019-10-03 00:00:00 发表: With editor已经三个月了，想撤稿, beContent=130****6528 2019-10-03 00:00:00 发表: With editor已经三个月了，想撤稿, objectType=tool_impact_factor, channel=null, level=null, likeNumber=147, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=17c95089935, createdName=145cf120m10(暂无昵称), createdTime=Tue Oct 08 00:00:00 CST 2019, time=2019-10-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2197970, encodeId=2f3a219e970d7, content=质量检查就10天了，崩溃, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=130, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6bbb4799156, createdName=2606467171, createdTime=Thu Apr 11 13:43:26 CST 2024, time=2024-04-11, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2243217, encodeId=14cd224321ecb, content=偏重的研究方向：白血病 经验分享：投了两篇letter，2个月了还是显示with editor ，求教各位大神正常吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTL8GV06roPeF96gmNNe5qicpI81qEbXLy1oKu8HDafssvuSfccR9UQIFkFFESxJ0ECOjgVoAt6QlaQ/132, createdBy=50201623070, createdName=wylj, createdTime=Wed Dec 18 06:28:28 CST 2024, time=2024-12-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2241787, encodeId=43762241e8705, content=我的投稿从系统里消失了，前几天还好好的，已经送外审了，从昨天点进去一看根本找不到我的文章了，也没有任何被拒的痕迹或者邮件，而且好像springer nature下的各期刊都没有自己的主页，所以我找不到annals of hematology可以联系的邮箱，大家有遇到过这种情况吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1f218759120, createdName=ms3000001014938846, createdTime=Wed Dec 11 09:58:30 CST 2024, time=2024-12-11, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2183703, encodeId=792f2183e038c, content=审稿速度:2.0 | 投稿命中率:75.0 经验分享：投白血病相关的综述，2个审稿人，提的意见比较中肯，审稿速度很快 2023-11-23 投稿 2023-11-28 editor assigned 2023-11-29 Under Review 2023-12-12 Major revision 2023-12-26 Submitted to journal 2023-12-27 Under Review 2024-01-15 minor revision 2024-01-16 Submitted to journal 2024-01-19 Submission accepted , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=147, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=775c5640894, createdName=ms8000000428100640, createdTime=Wed Jan 24 16:20:42 CST 2024, time=2024-01-24, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2164043, encodeId=1dea21640439d, content=审稿速度:1.0 | 投稿命中率:75.0 偏重的研究方向：肿瘤;血液病 经验分享：根据投稿指南要求修改排版，表达准确，图表清晰度够，审稿快，通过率高 2023-08-31投稿 2023-09-05 with editor 2023-09-01 Under Review 2023-09-19 Major revise 2023-10-13 Submitted to journal 203-10-16 Under Review 2023-10-20 accepted, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=267, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6a638109651, createdName=清清欢, createdTime=Sat Oct 21 07:35:27 CST 2023, time=2023-10-21, status=1, ipAttribution=江西省), GetPortalCommentsPageByObjectIdResponse(id=2125680, encodeId=4cce21256806c, content=2022.12.15投稿 2023.04.08 两个审稿人给了意见 2023.04.11修回 4.13接受编辑很客气, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=191, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210911/5888f6640265430b902b3fded856f491/788d7d25b2f7419ab0fab8df4239cea1.jpg, createdBy=c0775397989, createdName=凶巴巴恰北北怪兽, createdTime=Thu Apr 13 13:55:16 CST 2023, time=2023-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=926986, encodeId=b5b192698693, content=审稿速度:2.0 | 投稿命中率:50.0 经验分享：2020-09-04 投稿 2020-09-10 with editor 2020-10-02 Under Review 2020-11-11 Major Revision 2021-02-01 大修返回去 2021-02-02 with editor 2021-02-24 Accept 两个审稿人，大约提了20个问题，许多都是我们当时刻意回避的，审稿人都提出来了，在大修中认真回答审稿人的问题，让做亚组分析就做亚组分析，不能补充的内容就实话实说，告知审稿人我们的困难。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=337, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLfmR4mafTv9yhHTykjCcGOQP5acHwbYj07fiaDoT6p8jxes2icO8n9R8BD8t0LJmg1SjlPiaqWZn33g/132, createdBy=5c971339316, createdName=bright120, createdTime=Wed Feb 24 23:39:35 CST 2021, time=2021-02-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=574755, encodeId=e42c5e47558e, content=三个月了，一审还在under review。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=237, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/eunqL11r55A8WAWlyWs0EnafPqUs8awD2Jsk71ggkmlWicOGpfTScjbNxecDibU9J2TQjcVafFgY0hju6sfJS9rQ/132, createdBy=c6852367423, createdName=122e6881m72暂无昵称, createdTime=Tue Aug 13 21:09:00 CST 2019, time=2019-08-13, status=1, ipAttribution=)]

2024-04-11 2606467171 来自四川省

质量检查就10天了，崩溃

130 6

展开6条回复

[GetPortalCommentsPageByObjectIdResponse(id=2237488, encodeId=1155223e488ce, content=审稿速度:6.0 | 投稿命中率:50.0 偏重的研究方向：临床研究;移植预处理方案;前瞻，2期，单臂研究 经验分享：前期经过5次拒稿，我2024年1月14投稿Annals of hematology，2024年1月31编辑审核后送外审，2024年7月10日收到修改意见，2024年8月23收到文章被接受的消息，9月份线上发表，11月正式见刊，真的很开心，文章的顺利接受也带给我了信心，让我继续完成第二篇文章的创作，期待好的结果，也希望把这份好运气带给每一位投稿人，不管什么时候都不要放弃，你的文章一定会有属于它的一个家会接收它！加油，我们都很棒！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=42, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/202411/53b4a1217f3a4e079e3eaf104e804c09-leSA8mUKFk8P.jpg, createdBy=d5908847710, createdName=ms4000000203499871, createdTime=Sun Nov 17 22:09:53 CST 2024, time=2024-11-17, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=577471, encodeId=68545e74718d, content=我也130****6528 2019-10-03 00:00:00 发表: With editor已经三个月了，想撤稿, beContent=130****6528 2019-10-03 00:00:00 发表: With editor已经三个月了，想撤稿, objectType=tool_impact_factor, channel=null, level=null, likeNumber=147, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=17c95089935, createdName=145cf120m10(暂无昵称), createdTime=Tue Oct 08 00:00:00 CST 2019, time=2019-10-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2197970, encodeId=2f3a219e970d7, content=质量检查就10天了，崩溃, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=130, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6bbb4799156, createdName=2606467171, createdTime=Thu Apr 11 13:43:26 CST 2024, time=2024-04-11, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2243217, encodeId=14cd224321ecb, content=偏重的研究方向：白血病 经验分享：投了两篇letter，2个月了还是显示with editor ，求教各位大神正常吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTL8GV06roPeF96gmNNe5qicpI81qEbXLy1oKu8HDafssvuSfccR9UQIFkFFESxJ0ECOjgVoAt6QlaQ/132, createdBy=50201623070, createdName=wylj, createdTime=Wed Dec 18 06:28:28 CST 2024, time=2024-12-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2241787, encodeId=43762241e8705, content=我的投稿从系统里消失了，前几天还好好的，已经送外审了，从昨天点进去一看根本找不到我的文章了，也没有任何被拒的痕迹或者邮件，而且好像springer nature下的各期刊都没有自己的主页，所以我找不到annals of hematology可以联系的邮箱，大家有遇到过这种情况吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1f218759120, createdName=ms3000001014938846, createdTime=Wed Dec 11 09:58:30 CST 2024, time=2024-12-11, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2183703, encodeId=792f2183e038c, content=审稿速度:2.0 | 投稿命中率:75.0 经验分享：投白血病相关的综述，2个审稿人，提的意见比较中肯，审稿速度很快 2023-11-23 投稿 2023-11-28 editor assigned 2023-11-29 Under Review 2023-12-12 Major revision 2023-12-26 Submitted to journal 2023-12-27 Under Review 2024-01-15 minor revision 2024-01-16 Submitted to journal 2024-01-19 Submission accepted , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=147, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=775c5640894, createdName=ms8000000428100640, createdTime=Wed Jan 24 16:20:42 CST 2024, time=2024-01-24, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2164043, encodeId=1dea21640439d, content=审稿速度:1.0 | 投稿命中率:75.0 偏重的研究方向：肿瘤;血液病 经验分享：根据投稿指南要求修改排版，表达准确，图表清晰度够，审稿快，通过率高 2023-08-31投稿 2023-09-05 with editor 2023-09-01 Under Review 2023-09-19 Major revise 2023-10-13 Submitted to journal 203-10-16 Under Review 2023-10-20 accepted, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=267, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6a638109651, createdName=清清欢, createdTime=Sat Oct 21 07:35:27 CST 2023, time=2023-10-21, status=1, ipAttribution=江西省), GetPortalCommentsPageByObjectIdResponse(id=2125680, encodeId=4cce21256806c, content=2022.12.15投稿 2023.04.08 两个审稿人给了意见 2023.04.11修回 4.13接受编辑很客气, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=191, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210911/5888f6640265430b902b3fded856f491/788d7d25b2f7419ab0fab8df4239cea1.jpg, createdBy=c0775397989, createdName=凶巴巴恰北北怪兽, createdTime=Thu Apr 13 13:55:16 CST 2023, time=2023-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=926986, encodeId=b5b192698693, content=审稿速度:2.0 | 投稿命中率:50.0 经验分享：2020-09-04 投稿 2020-09-10 with editor 2020-10-02 Under Review 2020-11-11 Major Revision 2021-02-01 大修返回去 2021-02-02 with editor 2021-02-24 Accept 两个审稿人，大约提了20个问题，许多都是我们当时刻意回避的，审稿人都提出来了，在大修中认真回答审稿人的问题，让做亚组分析就做亚组分析，不能补充的内容就实话实说，告知审稿人我们的困难。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=337, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLfmR4mafTv9yhHTykjCcGOQP5acHwbYj07fiaDoT6p8jxes2icO8n9R8BD8t0LJmg1SjlPiaqWZn33g/132, createdBy=5c971339316, createdName=bright120, createdTime=Wed Feb 24 23:39:35 CST 2021, time=2021-02-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=574755, encodeId=e42c5e47558e, content=三个月了，一审还在under review。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=237, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/eunqL11r55A8WAWlyWs0EnafPqUs8awD2Jsk71ggkmlWicOGpfTScjbNxecDibU9J2TQjcVafFgY0hju6sfJS9rQ/132, createdBy=c6852367423, createdName=122e6881m72暂无昵称, createdTime=Tue Aug 13 21:09:00 CST 2019, time=2019-08-13, status=1, ipAttribution=)]

2024-12-18 wylj

偏重的研究方向：白血病
经验分享：投了两篇letter，2个月了还是显示with editor ，求教各位大神正常吗

21 0

[GetPortalCommentsPageByObjectIdResponse(id=2237488, encodeId=1155223e488ce, content=审稿速度:6.0 | 投稿命中率:50.0 偏重的研究方向：临床研究;移植预处理方案;前瞻，2期，单臂研究 经验分享：前期经过5次拒稿，我2024年1月14投稿Annals of hematology，2024年1月31编辑审核后送外审，2024年7月10日收到修改意见，2024年8月23收到文章被接受的消息，9月份线上发表，11月正式见刊，真的很开心，文章的顺利接受也带给我了信心，让我继续完成第二篇文章的创作，期待好的结果，也希望把这份好运气带给每一位投稿人，不管什么时候都不要放弃，你的文章一定会有属于它的一个家会接收它！加油，我们都很棒！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=42, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/202411/53b4a1217f3a4e079e3eaf104e804c09-leSA8mUKFk8P.jpg, createdBy=d5908847710, createdName=ms4000000203499871, createdTime=Sun Nov 17 22:09:53 CST 2024, time=2024-11-17, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=577471, encodeId=68545e74718d, content=我也130****6528 2019-10-03 00:00:00 发表: With editor已经三个月了，想撤稿, beContent=130****6528 2019-10-03 00:00:00 发表: With editor已经三个月了，想撤稿, objectType=tool_impact_factor, channel=null, level=null, likeNumber=147, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=17c95089935, createdName=145cf120m10(暂无昵称), createdTime=Tue Oct 08 00:00:00 CST 2019, time=2019-10-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2197970, encodeId=2f3a219e970d7, content=质量检查就10天了，崩溃, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=130, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6bbb4799156, createdName=2606467171, createdTime=Thu Apr 11 13:43:26 CST 2024, time=2024-04-11, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2243217, encodeId=14cd224321ecb, content=偏重的研究方向：白血病 经验分享：投了两篇letter，2个月了还是显示with editor ，求教各位大神正常吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTL8GV06roPeF96gmNNe5qicpI81qEbXLy1oKu8HDafssvuSfccR9UQIFkFFESxJ0ECOjgVoAt6QlaQ/132, createdBy=50201623070, createdName=wylj, createdTime=Wed Dec 18 06:28:28 CST 2024, time=2024-12-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2241787, encodeId=43762241e8705, content=我的投稿从系统里消失了，前几天还好好的，已经送外审了，从昨天点进去一看根本找不到我的文章了，也没有任何被拒的痕迹或者邮件，而且好像springer nature下的各期刊都没有自己的主页，所以我找不到annals of hematology可以联系的邮箱，大家有遇到过这种情况吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1f218759120, createdName=ms3000001014938846, createdTime=Wed Dec 11 09:58:30 CST 2024, time=2024-12-11, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2183703, encodeId=792f2183e038c, content=审稿速度:2.0 | 投稿命中率:75.0 经验分享：投白血病相关的综述，2个审稿人，提的意见比较中肯，审稿速度很快 2023-11-23 投稿 2023-11-28 editor assigned 2023-11-29 Under Review 2023-12-12 Major revision 2023-12-26 Submitted to journal 2023-12-27 Under Review 2024-01-15 minor revision 2024-01-16 Submitted to journal 2024-01-19 Submission accepted , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=147, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=775c5640894, createdName=ms8000000428100640, createdTime=Wed Jan 24 16:20:42 CST 2024, time=2024-01-24, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2164043, encodeId=1dea21640439d, content=审稿速度:1.0 | 投稿命中率:75.0 偏重的研究方向：肿瘤;血液病 经验分享：根据投稿指南要求修改排版，表达准确，图表清晰度够，审稿快，通过率高 2023-08-31投稿 2023-09-05 with editor 2023-09-01 Under Review 2023-09-19 Major revise 2023-10-13 Submitted to journal 203-10-16 Under Review 2023-10-20 accepted, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=267, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6a638109651, createdName=清清欢, createdTime=Sat Oct 21 07:35:27 CST 2023, time=2023-10-21, status=1, ipAttribution=江西省), GetPortalCommentsPageByObjectIdResponse(id=2125680, encodeId=4cce21256806c, content=2022.12.15投稿 2023.04.08 两个审稿人给了意见 2023.04.11修回 4.13接受编辑很客气, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=191, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210911/5888f6640265430b902b3fded856f491/788d7d25b2f7419ab0fab8df4239cea1.jpg, createdBy=c0775397989, createdName=凶巴巴恰北北怪兽, createdTime=Thu Apr 13 13:55:16 CST 2023, time=2023-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=926986, encodeId=b5b192698693, content=审稿速度:2.0 | 投稿命中率:50.0 经验分享：2020-09-04 投稿 2020-09-10 with editor 2020-10-02 Under Review 2020-11-11 Major Revision 2021-02-01 大修返回去 2021-02-02 with editor 2021-02-24 Accept 两个审稿人，大约提了20个问题，许多都是我们当时刻意回避的，审稿人都提出来了，在大修中认真回答审稿人的问题，让做亚组分析就做亚组分析，不能补充的内容就实话实说，告知审稿人我们的困难。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=337, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLfmR4mafTv9yhHTykjCcGOQP5acHwbYj07fiaDoT6p8jxes2icO8n9R8BD8t0LJmg1SjlPiaqWZn33g/132, createdBy=5c971339316, createdName=bright120, createdTime=Wed Feb 24 23:39:35 CST 2021, time=2021-02-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=574755, encodeId=e42c5e47558e, content=三个月了，一审还在under review。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=237, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/eunqL11r55A8WAWlyWs0EnafPqUs8awD2Jsk71ggkmlWicOGpfTScjbNxecDibU9J2TQjcVafFgY0hju6sfJS9rQ/132, createdBy=c6852367423, createdName=122e6881m72暂无昵称, createdTime=Tue Aug 13 21:09:00 CST 2019, time=2019-08-13, status=1, ipAttribution=)]

2024-12-11 ms3000001014938846 来自天津

我的投稿从系统里消失了，前几天还好好的，已经送外审了，从昨天点进去一看根本找不到我的文章了，也没有任何被拒的痕迹或者邮件，而且好像springer nature下的各期刊都没有自己的主页，所以我找不到annals of hematology可以联系的邮箱，大家有遇到过这种情况吗？

26 0

[GetPortalCommentsPageByObjectIdResponse(id=2237488, encodeId=1155223e488ce, content=审稿速度:6.0 | 投稿命中率:50.0 偏重的研究方向：临床研究;移植预处理方案;前瞻，2期，单臂研究 经验分享：前期经过5次拒稿，我2024年1月14投稿Annals of hematology，2024年1月31编辑审核后送外审，2024年7月10日收到修改意见，2024年8月23收到文章被接受的消息，9月份线上发表，11月正式见刊，真的很开心，文章的顺利接受也带给我了信心，让我继续完成第二篇文章的创作，期待好的结果，也希望把这份好运气带给每一位投稿人，不管什么时候都不要放弃，你的文章一定会有属于它的一个家会接收它！加油，我们都很棒！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=42, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/202411/53b4a1217f3a4e079e3eaf104e804c09-leSA8mUKFk8P.jpg, createdBy=d5908847710, createdName=ms4000000203499871, createdTime=Sun Nov 17 22:09:53 CST 2024, time=2024-11-17, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=577471, encodeId=68545e74718d, content=我也130****6528 2019-10-03 00:00:00 发表: With editor已经三个月了，想撤稿, beContent=130****6528 2019-10-03 00:00:00 发表: With editor已经三个月了，想撤稿, objectType=tool_impact_factor, channel=null, level=null, likeNumber=147, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=17c95089935, createdName=145cf120m10(暂无昵称), createdTime=Tue Oct 08 00:00:00 CST 2019, time=2019-10-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2197970, encodeId=2f3a219e970d7, content=质量检查就10天了，崩溃, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=130, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6bbb4799156, createdName=2606467171, createdTime=Thu Apr 11 13:43:26 CST 2024, time=2024-04-11, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2243217, encodeId=14cd224321ecb, content=偏重的研究方向：白血病 经验分享：投了两篇letter，2个月了还是显示with editor ，求教各位大神正常吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTL8GV06roPeF96gmNNe5qicpI81qEbXLy1oKu8HDafssvuSfccR9UQIFkFFESxJ0ECOjgVoAt6QlaQ/132, createdBy=50201623070, createdName=wylj, createdTime=Wed Dec 18 06:28:28 CST 2024, time=2024-12-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2241787, encodeId=43762241e8705, content=我的投稿从系统里消失了，前几天还好好的，已经送外审了，从昨天点进去一看根本找不到我的文章了，也没有任何被拒的痕迹或者邮件，而且好像springer nature下的各期刊都没有自己的主页，所以我找不到annals of hematology可以联系的邮箱，大家有遇到过这种情况吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1f218759120, createdName=ms3000001014938846, createdTime=Wed Dec 11 09:58:30 CST 2024, time=2024-12-11, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2183703, encodeId=792f2183e038c, content=审稿速度:2.0 | 投稿命中率:75.0 经验分享：投白血病相关的综述，2个审稿人，提的意见比较中肯，审稿速度很快 2023-11-23 投稿 2023-11-28 editor assigned 2023-11-29 Under Review 2023-12-12 Major revision 2023-12-26 Submitted to journal 2023-12-27 Under Review 2024-01-15 minor revision 2024-01-16 Submitted to journal 2024-01-19 Submission accepted , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=147, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=775c5640894, createdName=ms8000000428100640, createdTime=Wed Jan 24 16:20:42 CST 2024, time=2024-01-24, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2164043, encodeId=1dea21640439d, content=审稿速度:1.0 | 投稿命中率:75.0 偏重的研究方向：肿瘤;血液病 经验分享：根据投稿指南要求修改排版，表达准确，图表清晰度够，审稿快，通过率高 2023-08-31投稿 2023-09-05 with editor 2023-09-01 Under Review 2023-09-19 Major revise 2023-10-13 Submitted to journal 203-10-16 Under Review 2023-10-20 accepted, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=267, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6a638109651, createdName=清清欢, createdTime=Sat Oct 21 07:35:27 CST 2023, time=2023-10-21, status=1, ipAttribution=江西省), GetPortalCommentsPageByObjectIdResponse(id=2125680, encodeId=4cce21256806c, content=2022.12.15投稿 2023.04.08 两个审稿人给了意见 2023.04.11修回 4.13接受编辑很客气, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=191, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210911/5888f6640265430b902b3fded856f491/788d7d25b2f7419ab0fab8df4239cea1.jpg, createdBy=c0775397989, createdName=凶巴巴恰北北怪兽, createdTime=Thu Apr 13 13:55:16 CST 2023, time=2023-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=926986, encodeId=b5b192698693, content=审稿速度:2.0 | 投稿命中率:50.0 经验分享：2020-09-04 投稿 2020-09-10 with editor 2020-10-02 Under Review 2020-11-11 Major Revision 2021-02-01 大修返回去 2021-02-02 with editor 2021-02-24 Accept 两个审稿人，大约提了20个问题，许多都是我们当时刻意回避的，审稿人都提出来了，在大修中认真回答审稿人的问题，让做亚组分析就做亚组分析，不能补充的内容就实话实说，告知审稿人我们的困难。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=337, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLfmR4mafTv9yhHTykjCcGOQP5acHwbYj07fiaDoT6p8jxes2icO8n9R8BD8t0LJmg1SjlPiaqWZn33g/132, createdBy=5c971339316, createdName=bright120, createdTime=Wed Feb 24 23:39:35 CST 2021, time=2021-02-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=574755, encodeId=e42c5e47558e, content=三个月了，一审还在under review。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=237, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/eunqL11r55A8WAWlyWs0EnafPqUs8awD2Jsk71ggkmlWicOGpfTScjbNxecDibU9J2TQjcVafFgY0hju6sfJS9rQ/132, createdBy=c6852367423, createdName=122e6881m72暂无昵称, createdTime=Tue Aug 13 21:09:00 CST 2019, time=2019-08-13, status=1, ipAttribution=)]

2024-01-24 ms8000000428100640 来自四川省

审稿速度:2.0 | 投稿命中率:75.0
经验分享：投白血病相关的综述，2个审稿人，提的意见比较中肯，审稿速度很快
2023-11-23 投稿
2023-11-28 editor assigned
2023-11-29 Under Review
2023-12-12 Major revision
2023-12-26 Submitted to journal
2023-12-27 Under Review
2024-01-15 minor revision
2024-01-16 Submitted to journal
2024-01-19 Submission accepted

147 0

[GetPortalCommentsPageByObjectIdResponse(id=2237488, encodeId=1155223e488ce, content=审稿速度:6.0 | 投稿命中率:50.0 偏重的研究方向：临床研究;移植预处理方案;前瞻，2期，单臂研究 经验分享：前期经过5次拒稿，我2024年1月14投稿Annals of hematology，2024年1月31编辑审核后送外审，2024年7月10日收到修改意见，2024年8月23收到文章被接受的消息，9月份线上发表，11月正式见刊，真的很开心，文章的顺利接受也带给我了信心，让我继续完成第二篇文章的创作，期待好的结果，也希望把这份好运气带给每一位投稿人，不管什么时候都不要放弃，你的文章一定会有属于它的一个家会接收它！加油，我们都很棒！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=42, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/202411/53b4a1217f3a4e079e3eaf104e804c09-leSA8mUKFk8P.jpg, createdBy=d5908847710, createdName=ms4000000203499871, createdTime=Sun Nov 17 22:09:53 CST 2024, time=2024-11-17, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=577471, encodeId=68545e74718d, content=我也130****6528 2019-10-03 00:00:00 发表: With editor已经三个月了，想撤稿, beContent=130****6528 2019-10-03 00:00:00 发表: With editor已经三个月了，想撤稿, objectType=tool_impact_factor, channel=null, level=null, likeNumber=147, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=17c95089935, createdName=145cf120m10(暂无昵称), createdTime=Tue Oct 08 00:00:00 CST 2019, time=2019-10-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2197970, encodeId=2f3a219e970d7, content=质量检查就10天了，崩溃, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=130, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6bbb4799156, createdName=2606467171, createdTime=Thu Apr 11 13:43:26 CST 2024, time=2024-04-11, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2243217, encodeId=14cd224321ecb, content=偏重的研究方向：白血病 经验分享：投了两篇letter，2个月了还是显示with editor ，求教各位大神正常吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTL8GV06roPeF96gmNNe5qicpI81qEbXLy1oKu8HDafssvuSfccR9UQIFkFFESxJ0ECOjgVoAt6QlaQ/132, createdBy=50201623070, createdName=wylj, createdTime=Wed Dec 18 06:28:28 CST 2024, time=2024-12-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2241787, encodeId=43762241e8705, content=我的投稿从系统里消失了，前几天还好好的，已经送外审了，从昨天点进去一看根本找不到我的文章了，也没有任何被拒的痕迹或者邮件，而且好像springer nature下的各期刊都没有自己的主页，所以我找不到annals of hematology可以联系的邮箱，大家有遇到过这种情况吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1f218759120, createdName=ms3000001014938846, createdTime=Wed Dec 11 09:58:30 CST 2024, time=2024-12-11, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2183703, encodeId=792f2183e038c, content=审稿速度:2.0 | 投稿命中率:75.0 经验分享：投白血病相关的综述，2个审稿人，提的意见比较中肯，审稿速度很快 2023-11-23 投稿 2023-11-28 editor assigned 2023-11-29 Under Review 2023-12-12 Major revision 2023-12-26 Submitted to journal 2023-12-27 Under Review 2024-01-15 minor revision 2024-01-16 Submitted to journal 2024-01-19 Submission accepted , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=147, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=775c5640894, createdName=ms8000000428100640, createdTime=Wed Jan 24 16:20:42 CST 2024, time=2024-01-24, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2164043, encodeId=1dea21640439d, content=审稿速度:1.0 | 投稿命中率:75.0 偏重的研究方向：肿瘤;血液病 经验分享：根据投稿指南要求修改排版，表达准确，图表清晰度够，审稿快，通过率高 2023-08-31投稿 2023-09-05 with editor 2023-09-01 Under Review 2023-09-19 Major revise 2023-10-13 Submitted to journal 203-10-16 Under Review 2023-10-20 accepted, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=267, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6a638109651, createdName=清清欢, createdTime=Sat Oct 21 07:35:27 CST 2023, time=2023-10-21, status=1, ipAttribution=江西省), GetPortalCommentsPageByObjectIdResponse(id=2125680, encodeId=4cce21256806c, content=2022.12.15投稿 2023.04.08 两个审稿人给了意见 2023.04.11修回 4.13接受编辑很客气, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=191, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210911/5888f6640265430b902b3fded856f491/788d7d25b2f7419ab0fab8df4239cea1.jpg, createdBy=c0775397989, createdName=凶巴巴恰北北怪兽, createdTime=Thu Apr 13 13:55:16 CST 2023, time=2023-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=926986, encodeId=b5b192698693, content=审稿速度:2.0 | 投稿命中率:50.0 经验分享：2020-09-04 投稿 2020-09-10 with editor 2020-10-02 Under Review 2020-11-11 Major Revision 2021-02-01 大修返回去 2021-02-02 with editor 2021-02-24 Accept 两个审稿人，大约提了20个问题，许多都是我们当时刻意回避的，审稿人都提出来了，在大修中认真回答审稿人的问题，让做亚组分析就做亚组分析，不能补充的内容就实话实说，告知审稿人我们的困难。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=337, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLfmR4mafTv9yhHTykjCcGOQP5acHwbYj07fiaDoT6p8jxes2icO8n9R8BD8t0LJmg1SjlPiaqWZn33g/132, createdBy=5c971339316, createdName=bright120, createdTime=Wed Feb 24 23:39:35 CST 2021, time=2021-02-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=574755, encodeId=e42c5e47558e, content=三个月了，一审还在under review。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=237, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/eunqL11r55A8WAWlyWs0EnafPqUs8awD2Jsk71ggkmlWicOGpfTScjbNxecDibU9J2TQjcVafFgY0hju6sfJS9rQ/132, createdBy=c6852367423, createdName=122e6881m72暂无昵称, createdTime=Tue Aug 13 21:09:00 CST 2019, time=2019-08-13, status=1, ipAttribution=)]

2023-10-21 清清欢来自江西省

审稿速度:1.0 | 投稿命中率:75.0
偏重的研究方向：肿瘤;血液病
经验分享：根据投稿指南要求修改排版，表达准确，图表清晰度够，审稿快，通过率高 2023-08-31投稿 2023-09-05 with editor 2023-09-01 Under Review 2023-09-19 Major revise 2023-10-13 Submitted to journal 203-10-16 Under Review 2023-10-20 accepted

267 4

展开4条回复

[GetPortalCommentsPageByObjectIdResponse(id=2237488, encodeId=1155223e488ce, content=审稿速度:6.0 | 投稿命中率:50.0 偏重的研究方向：临床研究;移植预处理方案;前瞻，2期，单臂研究 经验分享：前期经过5次拒稿，我2024年1月14投稿Annals of hematology，2024年1月31编辑审核后送外审，2024年7月10日收到修改意见，2024年8月23收到文章被接受的消息，9月份线上发表，11月正式见刊，真的很开心，文章的顺利接受也带给我了信心，让我继续完成第二篇文章的创作，期待好的结果，也希望把这份好运气带给每一位投稿人，不管什么时候都不要放弃，你的文章一定会有属于它的一个家会接收它！加油，我们都很棒！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=42, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/202411/53b4a1217f3a4e079e3eaf104e804c09-leSA8mUKFk8P.jpg, createdBy=d5908847710, createdName=ms4000000203499871, createdTime=Sun Nov 17 22:09:53 CST 2024, time=2024-11-17, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=577471, encodeId=68545e74718d, content=我也130****6528 2019-10-03 00:00:00 发表: With editor已经三个月了，想撤稿, beContent=130****6528 2019-10-03 00:00:00 发表: With editor已经三个月了，想撤稿, objectType=tool_impact_factor, channel=null, level=null, likeNumber=147, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=17c95089935, createdName=145cf120m10(暂无昵称), createdTime=Tue Oct 08 00:00:00 CST 2019, time=2019-10-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2197970, encodeId=2f3a219e970d7, content=质量检查就10天了，崩溃, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=130, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6bbb4799156, createdName=2606467171, createdTime=Thu Apr 11 13:43:26 CST 2024, time=2024-04-11, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2243217, encodeId=14cd224321ecb, content=偏重的研究方向：白血病 经验分享：投了两篇letter，2个月了还是显示with editor ，求教各位大神正常吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTL8GV06roPeF96gmNNe5qicpI81qEbXLy1oKu8HDafssvuSfccR9UQIFkFFESxJ0ECOjgVoAt6QlaQ/132, createdBy=50201623070, createdName=wylj, createdTime=Wed Dec 18 06:28:28 CST 2024, time=2024-12-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2241787, encodeId=43762241e8705, content=我的投稿从系统里消失了，前几天还好好的，已经送外审了，从昨天点进去一看根本找不到我的文章了，也没有任何被拒的痕迹或者邮件，而且好像springer nature下的各期刊都没有自己的主页，所以我找不到annals of hematology可以联系的邮箱，大家有遇到过这种情况吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1f218759120, createdName=ms3000001014938846, createdTime=Wed Dec 11 09:58:30 CST 2024, time=2024-12-11, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2183703, encodeId=792f2183e038c, content=审稿速度:2.0 | 投稿命中率:75.0 经验分享：投白血病相关的综述，2个审稿人，提的意见比较中肯，审稿速度很快 2023-11-23 投稿 2023-11-28 editor assigned 2023-11-29 Under Review 2023-12-12 Major revision 2023-12-26 Submitted to journal 2023-12-27 Under Review 2024-01-15 minor revision 2024-01-16 Submitted to journal 2024-01-19 Submission accepted , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=147, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=775c5640894, createdName=ms8000000428100640, createdTime=Wed Jan 24 16:20:42 CST 2024, time=2024-01-24, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2164043, encodeId=1dea21640439d, content=审稿速度:1.0 | 投稿命中率:75.0 偏重的研究方向：肿瘤;血液病 经验分享：根据投稿指南要求修改排版，表达准确，图表清晰度够，审稿快，通过率高 2023-08-31投稿 2023-09-05 with editor 2023-09-01 Under Review 2023-09-19 Major revise 2023-10-13 Submitted to journal 203-10-16 Under Review 2023-10-20 accepted, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=267, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6a638109651, createdName=清清欢, createdTime=Sat Oct 21 07:35:27 CST 2023, time=2023-10-21, status=1, ipAttribution=江西省), GetPortalCommentsPageByObjectIdResponse(id=2125680, encodeId=4cce21256806c, content=2022.12.15投稿 2023.04.08 两个审稿人给了意见 2023.04.11修回 4.13接受编辑很客气, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=191, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210911/5888f6640265430b902b3fded856f491/788d7d25b2f7419ab0fab8df4239cea1.jpg, createdBy=c0775397989, createdName=凶巴巴恰北北怪兽, createdTime=Thu Apr 13 13:55:16 CST 2023, time=2023-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=926986, encodeId=b5b192698693, content=审稿速度:2.0 | 投稿命中率:50.0 经验分享：2020-09-04 投稿 2020-09-10 with editor 2020-10-02 Under Review 2020-11-11 Major Revision 2021-02-01 大修返回去 2021-02-02 with editor 2021-02-24 Accept 两个审稿人，大约提了20个问题，许多都是我们当时刻意回避的，审稿人都提出来了，在大修中认真回答审稿人的问题，让做亚组分析就做亚组分析，不能补充的内容就实话实说，告知审稿人我们的困难。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=337, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLfmR4mafTv9yhHTykjCcGOQP5acHwbYj07fiaDoT6p8jxes2icO8n9R8BD8t0LJmg1SjlPiaqWZn33g/132, createdBy=5c971339316, createdName=bright120, createdTime=Wed Feb 24 23:39:35 CST 2021, time=2021-02-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=574755, encodeId=e42c5e47558e, content=三个月了，一审还在under review。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=237, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/eunqL11r55A8WAWlyWs0EnafPqUs8awD2Jsk71ggkmlWicOGpfTScjbNxecDibU9J2TQjcVafFgY0hju6sfJS9rQ/132, createdBy=c6852367423, createdName=122e6881m72暂无昵称, createdTime=Tue Aug 13 21:09:00 CST 2019, time=2019-08-13, status=1, ipAttribution=)]

2023-04-13 凶巴巴恰北北怪兽

2022.12.15投稿 2023.04.08 两个审稿人给了意见 2023.04.11修回 4.13接受编辑很客气

191 2

展开2条回复

[GetPortalCommentsPageByObjectIdResponse(id=2237488, encodeId=1155223e488ce, content=审稿速度:6.0 | 投稿命中率:50.0 偏重的研究方向：临床研究;移植预处理方案;前瞻，2期，单臂研究 经验分享：前期经过5次拒稿，我2024年1月14投稿Annals of hematology，2024年1月31编辑审核后送外审，2024年7月10日收到修改意见，2024年8月23收到文章被接受的消息，9月份线上发表，11月正式见刊，真的很开心，文章的顺利接受也带给我了信心，让我继续完成第二篇文章的创作，期待好的结果，也希望把这份好运气带给每一位投稿人，不管什么时候都不要放弃，你的文章一定会有属于它的一个家会接收它！加油，我们都很棒！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=42, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/202411/53b4a1217f3a4e079e3eaf104e804c09-leSA8mUKFk8P.jpg, createdBy=d5908847710, createdName=ms4000000203499871, createdTime=Sun Nov 17 22:09:53 CST 2024, time=2024-11-17, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=577471, encodeId=68545e74718d, content=我也130****6528 2019-10-03 00:00:00 发表: With editor已经三个月了，想撤稿, beContent=130****6528 2019-10-03 00:00:00 发表: With editor已经三个月了，想撤稿, objectType=tool_impact_factor, channel=null, level=null, likeNumber=147, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=17c95089935, createdName=145cf120m10(暂无昵称), createdTime=Tue Oct 08 00:00:00 CST 2019, time=2019-10-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2197970, encodeId=2f3a219e970d7, content=质量检查就10天了，崩溃, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=130, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6bbb4799156, createdName=2606467171, createdTime=Thu Apr 11 13:43:26 CST 2024, time=2024-04-11, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2243217, encodeId=14cd224321ecb, content=偏重的研究方向：白血病 经验分享：投了两篇letter，2个月了还是显示with editor ，求教各位大神正常吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTL8GV06roPeF96gmNNe5qicpI81qEbXLy1oKu8HDafssvuSfccR9UQIFkFFESxJ0ECOjgVoAt6QlaQ/132, createdBy=50201623070, createdName=wylj, createdTime=Wed Dec 18 06:28:28 CST 2024, time=2024-12-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2241787, encodeId=43762241e8705, content=我的投稿从系统里消失了，前几天还好好的，已经送外审了，从昨天点进去一看根本找不到我的文章了，也没有任何被拒的痕迹或者邮件，而且好像springer nature下的各期刊都没有自己的主页，所以我找不到annals of hematology可以联系的邮箱，大家有遇到过这种情况吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1f218759120, createdName=ms3000001014938846, createdTime=Wed Dec 11 09:58:30 CST 2024, time=2024-12-11, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2183703, encodeId=792f2183e038c, content=审稿速度:2.0 | 投稿命中率:75.0 经验分享：投白血病相关的综述，2个审稿人，提的意见比较中肯，审稿速度很快 2023-11-23 投稿 2023-11-28 editor assigned 2023-11-29 Under Review 2023-12-12 Major revision 2023-12-26 Submitted to journal 2023-12-27 Under Review 2024-01-15 minor revision 2024-01-16 Submitted to journal 2024-01-19 Submission accepted , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=147, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=775c5640894, createdName=ms8000000428100640, createdTime=Wed Jan 24 16:20:42 CST 2024, time=2024-01-24, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2164043, encodeId=1dea21640439d, content=审稿速度:1.0 | 投稿命中率:75.0 偏重的研究方向：肿瘤;血液病 经验分享：根据投稿指南要求修改排版，表达准确，图表清晰度够，审稿快，通过率高 2023-08-31投稿 2023-09-05 with editor 2023-09-01 Under Review 2023-09-19 Major revise 2023-10-13 Submitted to journal 203-10-16 Under Review 2023-10-20 accepted, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=267, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6a638109651, createdName=清清欢, createdTime=Sat Oct 21 07:35:27 CST 2023, time=2023-10-21, status=1, ipAttribution=江西省), GetPortalCommentsPageByObjectIdResponse(id=2125680, encodeId=4cce21256806c, content=2022.12.15投稿 2023.04.08 两个审稿人给了意见 2023.04.11修回 4.13接受编辑很客气, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=191, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210911/5888f6640265430b902b3fded856f491/788d7d25b2f7419ab0fab8df4239cea1.jpg, createdBy=c0775397989, createdName=凶巴巴恰北北怪兽, createdTime=Thu Apr 13 13:55:16 CST 2023, time=2023-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=926986, encodeId=b5b192698693, content=审稿速度:2.0 | 投稿命中率:50.0 经验分享：2020-09-04 投稿 2020-09-10 with editor 2020-10-02 Under Review 2020-11-11 Major Revision 2021-02-01 大修返回去 2021-02-02 with editor 2021-02-24 Accept 两个审稿人，大约提了20个问题，许多都是我们当时刻意回避的，审稿人都提出来了，在大修中认真回答审稿人的问题，让做亚组分析就做亚组分析，不能补充的内容就实话实说，告知审稿人我们的困难。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=337, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLfmR4mafTv9yhHTykjCcGOQP5acHwbYj07fiaDoT6p8jxes2icO8n9R8BD8t0LJmg1SjlPiaqWZn33g/132, createdBy=5c971339316, createdName=bright120, createdTime=Wed Feb 24 23:39:35 CST 2021, time=2021-02-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=574755, encodeId=e42c5e47558e, content=三个月了，一审还在under review。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=237, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/eunqL11r55A8WAWlyWs0EnafPqUs8awD2Jsk71ggkmlWicOGpfTScjbNxecDibU9J2TQjcVafFgY0hju6sfJS9rQ/132, createdBy=c6852367423, createdName=122e6881m72暂无昵称, createdTime=Tue Aug 13 21:09:00 CST 2019, time=2019-08-13, status=1, ipAttribution=)]

2021-02-24 bright120

审稿速度:2.0 | 投稿命中率:50.0
经验分享：2020-09-04 投稿
2020-09-10 with editor
2020-10-02 Under Review
2020-11-11 Major Revision
2021-02-01 大修返回去
2021-02-02 with editor
2021-02-24 Accept
两个审稿人，大约提了20个问题，许多都是我们当时刻意回避的，审稿人都提出来了，在大修中认真回答审稿人的问题，让做亚组分析就做亚组分析，不能补充的内容就实话实说，告知审稿人我们的困难。

337 4

展开4条回复

[GetPortalCommentsPageByObjectIdResponse(id=2237488, encodeId=1155223e488ce, content=审稿速度:6.0 | 投稿命中率:50.0 偏重的研究方向：临床研究;移植预处理方案;前瞻，2期，单臂研究 经验分享：前期经过5次拒稿，我2024年1月14投稿Annals of hematology，2024年1月31编辑审核后送外审，2024年7月10日收到修改意见，2024年8月23收到文章被接受的消息，9月份线上发表，11月正式见刊，真的很开心，文章的顺利接受也带给我了信心，让我继续完成第二篇文章的创作，期待好的结果，也希望把这份好运气带给每一位投稿人，不管什么时候都不要放弃，你的文章一定会有属于它的一个家会接收它！加油，我们都很棒！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=42, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/202411/53b4a1217f3a4e079e3eaf104e804c09-leSA8mUKFk8P.jpg, createdBy=d5908847710, createdName=ms4000000203499871, createdTime=Sun Nov 17 22:09:53 CST 2024, time=2024-11-17, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=577471, encodeId=68545e74718d, content=我也130****6528 2019-10-03 00:00:00 发表: With editor已经三个月了，想撤稿, beContent=130****6528 2019-10-03 00:00:00 发表: With editor已经三个月了，想撤稿, objectType=tool_impact_factor, channel=null, level=null, likeNumber=147, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=17c95089935, createdName=145cf120m10(暂无昵称), createdTime=Tue Oct 08 00:00:00 CST 2019, time=2019-10-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2197970, encodeId=2f3a219e970d7, content=质量检查就10天了，崩溃, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=130, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6bbb4799156, createdName=2606467171, createdTime=Thu Apr 11 13:43:26 CST 2024, time=2024-04-11, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2243217, encodeId=14cd224321ecb, content=偏重的研究方向：白血病 经验分享：投了两篇letter，2个月了还是显示with editor ，求教各位大神正常吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTL8GV06roPeF96gmNNe5qicpI81qEbXLy1oKu8HDafssvuSfccR9UQIFkFFESxJ0ECOjgVoAt6QlaQ/132, createdBy=50201623070, createdName=wylj, createdTime=Wed Dec 18 06:28:28 CST 2024, time=2024-12-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2241787, encodeId=43762241e8705, content=我的投稿从系统里消失了，前几天还好好的，已经送外审了，从昨天点进去一看根本找不到我的文章了，也没有任何被拒的痕迹或者邮件，而且好像springer nature下的各期刊都没有自己的主页，所以我找不到annals of hematology可以联系的邮箱，大家有遇到过这种情况吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1f218759120, createdName=ms3000001014938846, createdTime=Wed Dec 11 09:58:30 CST 2024, time=2024-12-11, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2183703, encodeId=792f2183e038c, content=审稿速度:2.0 | 投稿命中率:75.0 经验分享：投白血病相关的综述，2个审稿人，提的意见比较中肯，审稿速度很快 2023-11-23 投稿 2023-11-28 editor assigned 2023-11-29 Under Review 2023-12-12 Major revision 2023-12-26 Submitted to journal 2023-12-27 Under Review 2024-01-15 minor revision 2024-01-16 Submitted to journal 2024-01-19 Submission accepted , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=147, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=775c5640894, createdName=ms8000000428100640, createdTime=Wed Jan 24 16:20:42 CST 2024, time=2024-01-24, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2164043, encodeId=1dea21640439d, content=审稿速度:1.0 | 投稿命中率:75.0 偏重的研究方向：肿瘤;血液病 经验分享：根据投稿指南要求修改排版，表达准确，图表清晰度够，审稿快，通过率高 2023-08-31投稿 2023-09-05 with editor 2023-09-01 Under Review 2023-09-19 Major revise 2023-10-13 Submitted to journal 203-10-16 Under Review 2023-10-20 accepted, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=267, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6a638109651, createdName=清清欢, createdTime=Sat Oct 21 07:35:27 CST 2023, time=2023-10-21, status=1, ipAttribution=江西省), GetPortalCommentsPageByObjectIdResponse(id=2125680, encodeId=4cce21256806c, content=2022.12.15投稿 2023.04.08 两个审稿人给了意见 2023.04.11修回 4.13接受编辑很客气, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=191, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210911/5888f6640265430b902b3fded856f491/788d7d25b2f7419ab0fab8df4239cea1.jpg, createdBy=c0775397989, createdName=凶巴巴恰北北怪兽, createdTime=Thu Apr 13 13:55:16 CST 2023, time=2023-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=926986, encodeId=b5b192698693, content=审稿速度:2.0 | 投稿命中率:50.0 经验分享：2020-09-04 投稿 2020-09-10 with editor 2020-10-02 Under Review 2020-11-11 Major Revision 2021-02-01 大修返回去 2021-02-02 with editor 2021-02-24 Accept 两个审稿人，大约提了20个问题，许多都是我们当时刻意回避的，审稿人都提出来了，在大修中认真回答审稿人的问题，让做亚组分析就做亚组分析，不能补充的内容就实话实说，告知审稿人我们的困难。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=337, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLfmR4mafTv9yhHTykjCcGOQP5acHwbYj07fiaDoT6p8jxes2icO8n9R8BD8t0LJmg1SjlPiaqWZn33g/132, createdBy=5c971339316, createdName=bright120, createdTime=Wed Feb 24 23:39:35 CST 2021, time=2021-02-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=574755, encodeId=e42c5e47558e, content=三个月了，一审还在under review。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=237, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/eunqL11r55A8WAWlyWs0EnafPqUs8awD2Jsk71ggkmlWicOGpfTScjbNxecDibU9J2TQjcVafFgY0hju6sfJS9rQ/132, createdBy=c6852367423, createdName=122e6881m72暂无昵称, createdTime=Tue Aug 13 21:09:00 CST 2019, time=2019-08-13, status=1, ipAttribution=)]

2019-08-13 122e6881m72暂无昵称

三个月了，一审还在under review。。。

237 1

展开1条回复

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

期刊讨论

科室

工具

服务